NCT00017472 - Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

April 30, 2006

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Marginal Zone LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaStage III Marginal Zone LymphomaStage III Small Lymphocytic LymphomaStage IV Marginal Zone LymphomaStage IV Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL

apolizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH